Head to Head Review: Allurion Technologies (NYSE:ALUR) vs. Monogram Orthopaedics (NASDAQ:MGRM)

Monogram Orthopaedics (NASDAQ:MGRM) and Allurion Technologies (NYSE:ALUR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, earnings, dividends and profitability.

Valuation and Earnings

This table compares Monogram Orthopaedics and Allurion Technologies”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monogram Orthopaedics	$364,999.00	213.45	-$13.74 million	($0.50)	-4.92
Allurion Technologies	$47.59 million	0.71	-$80.61 million	($3.79)	-0.19

Monogram Orthopaedics has higher earnings, but lower revenue than Allurion Technologies. Monogram Orthopaedics is trading at a lower price-to-earnings ratio than Allurion Technologies, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Monogram Orthopaedics has a beta of 2.22, suggesting that its stock price is 122% more volatile than the S&P 500. Comparatively, Allurion Technologies has a beta of -0.33, suggesting that its stock price is 133% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and recommmendations for Monogram Orthopaedics and Allurion Technologies, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monogram Orthopaedics	0	0	0	0	N/A
Allurion Technologies	0	0	4	1	3.20

Allurion Technologies has a consensus price target of $2.88, indicating a potential upside of 307.80%. Given Allurion Technologies’ higher possible upside, analysts clearly believe Allurion Technologies is more favorable than Monogram Orthopaedics.

Insider and Institutional Ownership

0.4% of Monogram Orthopaedics shares are owned by institutional investors. Comparatively, 21.4% of Allurion Technologies shares are owned by institutional investors. 32.1% of Monogram Orthopaedics shares are owned by insiders. Comparatively, 20.0% of Allurion Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Monogram Orthopaedics and Allurion Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Monogram Orthopaedics	N/A	-109.96%	-81.82%
Allurion Technologies	-78.56%	N/A	-64.22%

Summary

Allurion Technologies beats Monogram Orthopaedics on 8 of the 14 factors compared between the two stocks.

About Monogram Orthopaedics

Monogram Orthopaedics, Inc. focuses on developing a product solution architecture to enable patient-optimized orthopaedic implants. The company intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation for use in reconstructive joint replacement procedures. Its robot prototype executes optimized paths for high-precision insertion of optimized implants in synthetic bone specimens. The company was formerly known as Monogram Arthroplasty Inc. and changed its name to Monogram Orthopaedics, Inc. in March 2017. The company was founded in 2015 and is headquartered in Austin, Texas.

About Allurion Technologies

Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. Allurion Technologies Inc. is headquartered in Natick, Massachusetts.